102,999 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 102,999 shares of the company’s stock, valued at approximately $4,299,000. Renaissance Technologies LLC owned approximately 0.32% of TransMedics Group as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. Legal & General Group Plc boosted its position in TransMedics Group by 4.9% during the 2nd quarter. Legal & General Group Plc now owns 13,502 shares of the company’s stock worth $425,000 after acquiring an additional 631 shares during the last quarter. Amalgamated Bank raised its stake in TransMedics Group by 17.2% in the 3rd quarter. Amalgamated Bank now owns 4,935 shares of the company’s stock valued at $206,000 after acquiring an additional 725 shares during the period. Arizona State Retirement System raised its stake in TransMedics Group by 13.2% in the 3rd quarter. Arizona State Retirement System now owns 8,092 shares of the company’s stock valued at $338,000 after acquiring an additional 943 shares during the period. Advisor Group Holdings Inc. raised its stake in TransMedics Group by 7.8% in the 1st quarter. Advisor Group Holdings Inc. now owns 13,173 shares of the company’s stock valued at $354,000 after acquiring an additional 948 shares during the period. Finally, MCF Advisors LLC bought a new position in TransMedics Group during the 3rd quarter worth $43,000. 88.58% of the stock is owned by institutional investors.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $71.52 on Monday. The stock has a 50-day simple moving average of $67.12 and a two-hundred day simple moving average of $57.33. The firm has a market capitalization of $2.30 billion, a P/E ratio of -57.22 and a beta of 1.47. TransMedics Group, Inc. has a fifty-two week low of $16.70 and a fifty-two week high of $83.48. The company has a debt-to-equity ratio of 0.31, a quick ratio of 9.79 and a current ratio of 10.66.

TransMedics Group (NASDAQ:TMDX – Get Rating) last issued its earnings results on Wednesday, February 22nd. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.07. The business had revenue of $31.38 million for the quarter, compared to analysts’ expectations of $23.60 million. TransMedics Group had a negative return on equity of 29.82% and a negative net margin of 38.77%. The business’s revenue for the quarter was up 224.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.46) EPS. On average, equities analysts forecast that TransMedics Group, Inc. will post -0.89 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TMDX. Canaccord Genuity Group raised their price objective on TransMedics Group from $68.00 to $78.00 and gave the company a “buy” rating in a research note on Thursday, February 23rd. Morgan Stanley lifted their target price on TransMedics Group from $63.00 to $74.00 and gave the stock an “equal weight” rating in a report on Thursday, February 23rd. Oppenheimer lifted their target price on TransMedics Group from $55.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, February 23rd. Cowen upped their price target on TransMedics Group from $70.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, February 23rd. Finally, JPMorgan Chase & Co. upped their target price on TransMedics Group from $67.00 to $81.00 and gave the stock an “overweight” rating in a research note on Thursday, February 23rd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.57.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, VP Laura Damme sold 4,990 shares of the stock in a transaction dated Thursday, December 15th. The shares were sold at an average price of $59.01, for a total value of $294,459.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other TransMedics Group news, VP Miriam Provost sold 4,315 shares of the firm’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $62.53, for a total transaction of $269,816.95. Following the completion of the transaction, the vice president now directly owns 15,154 shares of the company’s stock, valued at approximately $947,579.62. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Laura Damme sold 4,990 shares of the firm’s stock in a transaction on Thursday, December 15th. The stock was sold at an average price of $59.01, for a total transaction of $294,459.90. The disclosure for this sale can be found here. Insiders sold 183,843 shares of company stock worth $13,072,294 over the last 90 days. Corporate insiders own 8.70% of the company’s stock.

TransMedics Group Company Profile

(Get Rating)

TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.